Abstract 46P
Background
The mechanism of PD-1 inhibitors-induced myocarditis in individuals with tumor is still unclear. Regulatory T cells (Treg) can directly inhibit T cell proliferation and activation, and also produce inhibitory cytokines with potent immunosuppressive properties. Deletion or aberrant function of Treg usually leads to autoimmune diseases. But reports on the role of Treg in PD-1 inhibitor-associated myocarditis are still very limited, and its role in the pathogenesis of myocarditis needs to be further explored. In addition, alterations in the composition of the gut microbiota and its metabolites have been shown to be involved in the development of several cardiovascular and autoimmune diseases.
Methods
We first established a melanoma model in mice, which were subsequently divided into three groups: control group, Anti-PD1 group and fecal microbiota removal (FMR) group. The control group and Anti-PD1 group were subcutaneously injected with mouse IgG and PD-1 inhibitors respectively, and FMR group were injected with PD-1 inhibitors subcutaneously along with oral antibiotic antimicrobials to clear the intestinal microbiota. Afterwards, we assessed the severity of myocarditis in mice, performed flow cytometry analysis of immune cells in the heart, determined transcript levels of Treg-related cytokines in the heart, and performed 16S rRNA gene sequence analysis of gut microbiota and correlation analysis of enriched gut microbiota with myocarditis factors.
Results
PD-1 inhibitors induced myocarditis in melanoma mice, leading to a reduction in intracardiac Tregs and downregulation of inflammatory suppressor transcript levels, as well as altering the gut microbial composition of the mice. However, in the presence of gut microbial removal, myocarditis manifestations in the mice described above were attenuated. In addition, microbes enriched in the gut of mice after treatment with PD-1 inhibitors showed a strong correlation with factors associated with the development of myocarditis.
Conclusions
PD-1 inhibitors induced myocarditis and significant reduction of intracardiac Treg in melanoma mice. It is highly likely that alterations in the composition of the gut microbiota due to PD-1 inhibitors played a key role in this process.
Legal entity responsible for the study
The authors.
Funding
Shanxi Provincial Health Commission.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract